Boobalan Pachaiyappan
Stock Analyst at Roth Capital
(4.60)
# 218
Out of 5,154 analysts
23
Total ratings
66.67%
Success rate
40.06%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Boobalan Pachaiyappan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OVID Ovid Therapeutics | Initiates: Buy | $3 | $1.91 | +57.07% | 1 | Dec 11, 2025 | |
| CING Cingulate | Maintains: Buy | $17 → $16 | $6.43 | +148.83% | 4 | Nov 19, 2025 | |
| PYPD PolyPid | Maintains: Buy | $10 → $9 | $4.19 | +114.80% | 3 | Nov 13, 2025 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $12 → $13 | $27.90 | -53.41% | 3 | Nov 12, 2025 | |
| RVPH Reviva Pharmaceuticals Holdings | Reiterates: Buy | $7 → $3 | $0.18 | +1,579.73% | 2 | Aug 18, 2025 | |
| LGVN Longeveron | Maintains: Buy | $10 → $3 | $0.48 | +520.35% | 2 | Aug 15, 2025 | |
| GANX Gain Therapeutics | Maintains: Buy | $7 → $6 | $3.05 | +96.72% | 3 | Aug 13, 2025 | |
| CRVO CervoMed | Reiterates: Buy | $20 → $16 | $4.11 | +289.29% | 4 | Aug 12, 2025 | |
| TRDA Entrada Therapeutics | Initiates: Buy | $29 | $12.58 | +130.52% | 1 | Dec 5, 2024 |
Ovid Therapeutics
Dec 11, 2025
Initiates: Buy
Price Target: $3
Current: $1.91
Upside: +57.07%
Cingulate
Nov 19, 2025
Maintains: Buy
Price Target: $17 → $16
Current: $6.43
Upside: +148.83%
PolyPid
Nov 13, 2025
Maintains: Buy
Price Target: $10 → $9
Current: $4.19
Upside: +114.80%
Capricor Therapeutics
Nov 12, 2025
Maintains: Buy
Price Target: $12 → $13
Current: $27.90
Upside: -53.41%
Reviva Pharmaceuticals Holdings
Aug 18, 2025
Reiterates: Buy
Price Target: $7 → $3
Current: $0.18
Upside: +1,579.73%
Longeveron
Aug 15, 2025
Maintains: Buy
Price Target: $10 → $3
Current: $0.48
Upside: +520.35%
Gain Therapeutics
Aug 13, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $3.05
Upside: +96.72%
CervoMed
Aug 12, 2025
Reiterates: Buy
Price Target: $20 → $16
Current: $4.11
Upside: +289.29%
Entrada Therapeutics
Dec 5, 2024
Initiates: Buy
Price Target: $29
Current: $12.58
Upside: +130.52%